Literature DB >> 29516691

[On the Considerations About Heating Materials and Temperature of Moxibustion in Clinical Practice].

Bing Zhu1.   

Abstract

Moxibustion, one of the traditional Chinese medicine therapy, plays an important role in the treatment of a variety of clinical conditions, particularly the chronic and deficiency problems. In the present paper, the author reviewed the history of development of moxibustion therapy, and the related materials and heating temperature in ancient China, and also reviewed the history of heating therapy (similar to moxibustion) appearing in ancient Egypt, Greek, Libya, India, Europe, etc. The author thinks that the efficacy of moxibustion intervention mainly depends on the heating temperature and the heated area of the skin (not the heating materials) according to his own research group's experimental outcomes. Some problems of moxibustion should be noted, for example, the ignited moxa-smoke induced environmental contamination which may lead to chronic injury particularly to the health of the related practitioners. The author forecasts that some succedaneous materials of mugwort as physical heating energy (mechanical, electrical, microelectronic, solar energy), chemical, biological and medical heating reagents (acupoint receptor-activator), etc., high technique medical devices are probably developed in the future, minimizing some defects of moxa and expanding clinical application of moxibustion therapy.

Entities:  

Keywords:  Efficacy of moxibustion; Heating area; Heating materials; Heating temperature

Mesh:

Year:  2018        PMID: 29516691     DOI: 10.13702/j.1000-0607.171000

Source DB:  PubMed          Journal:  Zhen Ci Yan Jiu        ISSN: 1000-0607


  1 in total

1.  Mitochondrial Respiratory Chain and Its Regulatory Elements SIRT1 and SIRT3 Play Important Role in the Initial Process of Energy Conversion after Moxibustion at Local Skin.

Authors:  Ning Zhang; Na Zhao; Lu-Shuang Xie; Biao Huang; Si-Rui Lin; Qun Zhang; Yuan-Bing Zhu; Qiao-Feng Wu; Shu-Guang Yu
Journal:  Evid Based Complement Alternat Med       Date:  2020-08-21       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.